A distinct approach of CD47 blockade via magrolimab in combination with azacytidine showed favorable outcomes in both TP53-mutant (40% CR, median OS 16.3 months) and wild-type patients with high-risk MDS (31% CR, median OS NR) (55). Here, TP53 is linked to myelodysplastic syndrome.